Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, while tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release to reduce visceral fat, primarily in HIV-positive patients with lipodystrophy
Direct mechanisms may involve GLP-1 receptor activation on vascular endothelial cells, whilst indirect effects result from weight loss, improved glycaemic control, and reduced visceral adiposity, all of which independently lower inflammatory burden
Mild to moderate dehydration (the most common pattern) gets coded as fatigue, dizziness, or headache instead
McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB et al
Energy levels often increase during this foundational period as cellular inflammation decreases despite professional stressors you navigate
When your vial looks different from last time Mochi patients sometimes receive vials that look different from their previous shipment
